This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Alicia Martin and attendees of the KEMRI-Wellcome Trust/GINGER Bioinformatics training in Kilifi, Kenya in September 2018. Alicia Martin, Allan Kalungi (Makerere University), and Lerato Majara (University of Cape Town) work together on a research project at the 2018 GINGER workshop held in London, UK.
Pamer joined the University of Chicago from Memorial Sloan Kettering Cancer Center in New York City, where he served as head of the Division of Subspecialty Medicine from 2011 to 2018 and director of the Center for Microbes, Inflammation and Cancer from 2010 to 2019. Diversigen, Inc.
Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.
Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Using powerful bioinformatics technology developed and validated with sequence data from the TRACERx study, researchers are able to identify clonal neoantigens from a patient’s unique tumour profile.
Artificial Life (2018). Nature Biotechnology (2018). Science (2018). eLife (2018). Link Modelling and analysis of gene regulatory networks , by Karlebach G. & & Shamir R. Nature Reviews Molecular Cell Biology (2008). Link Artificial Gene Regulatory Networks—A Review , by Cussat-Blanc S. Science (2017).
Artificial Life (2018). Nature Biotechnology (2018). Science (2018). eLife (2018). Link Modelling and analysis of gene regulatory networks , by Karlebach G. & & Shamir R. Nature Reviews Molecular Cell Biology (2008). Link Artificial Gene Regulatory Networks—A Review , by Cussat-Blanc S. Science (2017).
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content